STOCK TITAN
  1. Home
  2. Sec-filings
  3. TELO
  4. [8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported a leadership change in its finance function. Effective June 6, 2026, Alan Weichselbaum will no longer serve as Chief Financial Officer, with the company stating his departure is not due to any disagreement over operations, policies, or practices. On June 3, 2026, the board appointed Andriy Mushak, a Massachusetts-licensed CPA with over 20 years of SEC reporting and audit experience, as fractional Chief Financial Officer. Mushak will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will receive $6,000 per month. The company notes he has no disclosable related-party relationships or transactions with current executives or directors.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Fractional CFO fee $6,000 per month Consulting compensation for Andriy Mushak as fractional CFO
fractional Chief Financial Officer financial
"appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer"
Consulting Agreement financial
"providing his services pursuant to the Consulting Agreement between the Company and LMAM"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001971532 0001971532 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 3, 2026

 

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida   001-41952   87-2606031
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (786) 396-6723

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, no par value   TELO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Appointment of Andriy Mushak as the Fractional Chief Financial Officer

 

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the “Company”). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

 

Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co-founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.

 

Mr. Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered by Mr. Mushak.

 

There are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Mushak and any of the Company’s executive officers or directors or persons nominated or chosen to become a director or executive officer.

 

Mr. Mushak has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

10.1   Consulting Agreement between Telomir Pharmaceuticals, Inc. LMAM Consulting Group, LLC
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TELOMIR PHARMACEUTICALS, INC.
     
Dated: June 8, 2026 By: /s/ Erez Aminov           
  Name: Erez Aminov
  Title: Chief Executive Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did Telomir Pharmaceuticals (TELO) disclose in this 8-K?

Telomir Pharmaceuticals disclosed that Alan Weichselbaum will cease serving as Chief Financial Officer on June 6, 2026. The board appointed Andriy Mushak as fractional CFO, providing continuity in the company’s finance leadership role through a consulting arrangement.

Why did Telomir Pharmaceuticals say its CFO, Alan Weichselbaum, is leaving?

The company stated that Alan Weichselbaum’s departure as Chief Financial Officer was not due to any disagreement regarding its operations, policies, or practices. This language aims to reassure investors that the change is not tied to internal disputes or accounting concerns.

Who is Andriy Mushak, the new fractional CFO of Telomir Pharmaceuticals (TELO)?

Andriy Mushak is a Certified Public Accountant licensed in Massachusetts with over 20 years of SEC reporting and audit experience. He is a partner at LMAM Consulting Group, leading SEC reporting, financial statement preparation, and advisory services for public and private companies.

How will Telomir Pharmaceuticals compensate its new fractional CFO Andriy Mushak?

Telomir Pharmaceuticals will pay Andriy Mushak $6,000 per month for his services as fractional Chief Financial Officer. He will provide these services through LMAM Consulting Group under a consulting agreement between the company and that professional services firm.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents